Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
81-100 of 1,743 trials

Triple-Negative Breast Cancer: Tiragolumab and Atezolizumab with Chemotherapy

We are studying a combination of two immunotherapy drugs with chemotherapy for patients with triple-negative breast cancer. This trial aims to evaluate the treatment's effectiveness and safety in both early and advanced stages of the disease.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: MK-1084 Treatment

We are testing a new drug, MK-1084, for patients with advanced solid tumors that have a KRAS mutation. This study aims to understand its safety and how it may help in treating these tumors.

Solid Tumor Cancer>2 yearsSafety phase (I)Oncology

Solid Tumors: AZD9592 Treatment Study

We are testing a new drug called AZD9592 for patients with solid tumors. The goal is to learn more about its safety and how it may help in treating cancer.

Metastatic Colorectal CancerRecurrent or Metastatic Head and Neck Squamous Cell CarcinomaLocally Advanced or Metastatic Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: ASP3082 Study

We are investigating a new treatment called ASP3082 for adults with advanced solid tumors. The goal is to learn more about its effects and safety in this patient group.

Solid Tumor>2 yearsSafety phase (I)Oncology

Stroke Prevention in Kidney Disease: Apixaban Study

We are studying whether apixaban can safely reduce the risk of strokes in patients with chronic kidney disease stage 5 and atrial fibrillation. This trial will help us understand its effects compared to standard care.

Atrial Fibrillation with Chronic Kidney Disease Stage 5>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal MedicineNephrology

Ovarian Cancer: Mirvetuximab Soravtansine with Bevacizumab

We are studying a new treatment combining mirvetuximab soravtansine and bevacizumab for adults with recurrent ovarian cancer who have not progressed after chemotherapy. The goal is to see if this combination helps patients live longer without their cancer worsening.

Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Long-Term Safety of Miltenyi CAR T Cell Therapy

We are studying the long-term effects of Miltenyi CAR T cell therapy on patients, especially children. This includes monitoring safety, disease progression, and overall survival.

Unresectable Stage III or IV MelanomaRelapsed or Refractory B Cell Non-Hodgkin's LymphomaRelapsed or Refractory CD20 Positive B-Cell Non-Hodgkin’s Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyHematologyOncology

Kidney Transplant: Belatacept vs. Calcineurin Inhibitors

We are studying whether switching to a new immunosuppressive medication helps adolescent kidney transplant recipients maintain their health better than staying on their current treatment. This trial focuses on patients aged 12 to under 18 years.

Kidney Transplant>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Advanced Solid Tumors: Denikitug Treatment Study

We are testing a new antibody treatment for adults with advanced solid tumors to see if it is safe and effective. This study looks at the treatment alone and in combination with another therapy.

Various Types of Cancer>2 yearsSafety phase (I)Oncology

Neuroblastoma: Comparing PET-CT and SPECT-CT Scans

We are studying whether a new PET-CT scan can better detect lesions in patients with neuroblastoma compared to a standard SPECT-CT scan. This may help improve diagnosis and treatment options for patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Novel Amino Acid PET Tracer: [18F]FELP

We are testing a new imaging agent to see how well it works in detecting certain diseases. This study aims to improve the accuracy of PET scans for better diagnosis.

Glioblastoma>2 yearsSafety phase (I)Oncology

Advanced Non-Clear Cell Kidney Cancer: XL092 + Nivolumab

We are studying a new treatment combination for patients with advanced or metastatic non-clear cell kidney cancer. The goal is to see if it works better and is safer than the standard treatment.

Advanced Non-Clear Cell Renal Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

T-Cell Lymphoma: Autologous Stem Cell Transplantation Study

We are investigating whether autologous stem cell transplantation helps patients with T-cell lymphoma who have responded well to initial chemotherapy. This study aims to see if it improves their chances of staying cancer-free longer.

Peripheral T-cell Lymphoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOncology

GD2 Positive Solid Cancers: GD2IL18CART Treatment

We are testing a new therapy called GD2IL18CART for patients with relapsed or hard-to-treat GD2 positive solid cancers. The study aims to assess safety, find the right dose, and evaluate how well the treatment works.

NeuroblastomaAdvanced Breast CancerEwing Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Blood Cancer Treatment: Allo-RevCAR01-T-CD123

We are testing a new therapy for patients with certain blood cancers that have CD123 markers. This study aims to evaluate the safety and dosage of this innovative treatment.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Mantle Cell Lymphoma: Venetoclax with Ibrutinib and Rituximab

We are studying a new treatment combination for patients with Mantle Cell Lymphoma who cannot undergo high-dose therapy. The goal is to see how well it works compared to standard chemotherapy.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Marginal Zone Lymphoma: Mosunetuzumab-Lenalidomide Study

We are investigating whether the combination of Mosunetuzumab and Lenalidomide is more effective than standard treatments for patients with relapsed or refractory Marginal Zone Lymphoma. The study aims to assess how well this new treatment works and its safety.

Marginal Zone Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Myeloma: [68Ga]Ga-PentixaFor PET Imaging Study

We are studying a new imaging method to see how accurately it detects myeloma at the beginning of treatment. This may help improve risk assessment and disease management for patients.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Small-Cell Lung Cancer: BI 764532 Study

We are testing how well the drug BI 764532 is taken up by tumors in patients with small-cell lung cancer or neuroendocrine cancer. This study aims to understand its potential effectiveness in treating these cancers.

Advanced CancerLarge Cell Neuroendocrine Lung Carcinoma (LCNEC)Neuroendocrine Carcinoma (NEC)>2 yearsSafety phase (I)Oncology

Glioblastoma: L19TNF and Lomustine Study

We are evaluating a new treatment combining L19TNF with lomustine for patients with glioblastoma at their first progression. This study aims to understand how safe and effective this combination is.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology